Dishman Carbogen Amcis is a global outsourcing partner for the pharmaceutical industry, headquartered in Ahmedabad, India. With a strong presence across Europe, North America, and Asia, the company specializes in contract research and manufacturing services (CRAMS), catering to the full lifecycle of drug development—from early-stage discovery to commercial production. Backed by decades of scientific expertise and a commitment to quality, Dishman Carbogen Amcis supports leading pharma and biotech companies in bringing complex molecules and high-potency APIs to market efficiently and safely. Its integrated solutions and global footprint make it a trusted partner in accelerating innovation in healthcare.
The leadership at Dishman Carbogen Amcis is driven by deep industry knowledge and a global vision for pharmaceutical innovation:
Dr. Vyas is the founder and guiding force behind Dishman Carbogen Amcis. With over four decades of experience in the chemical and pharmaceutical industry, he has played a pivotal role in transforming the company into a globally recognized CRAMS (Contract Research and Manufacturing Services) provider. Under his leadership, Dishman expanded its international presence and developed advanced capabilities in high-potency APIs and complex chemistry services. He continues to spearhead strategic growth initiatives for the group.
Managing Director, Dishman Group Arpit Vyas brings a blend of strategic insight and operational expertise to the organization. As Managing Director, he is responsible for streamlining operations, expanding global partnerships, and driving sustainable growth. He has been instrumental in enhancing the company's technological and manufacturing capabilities, aligning them with evolving customer needs in global pharmaceutical markets.
As of March 31, 2024, Dishman Carbogen Amcis reported consolidated revenue of ₹2,666 crore, marking a 9.3% increase from ₹2,441 crore in FY23. Despite the revenue growth, the company recorded a net loss of ₹153 crore in FY24, compared to a net loss of ₹29.8 crore in FY23. The EBITDA for FY24 stood at ₹409 crore, slightly down from ₹414 crore in the previous fiscal year
As of March 2025, Dishman Carbogen Amcis Limited holds a credit rating of IND A+ / Stable from India Ratings, reflecting an adequate degree of safety regarding timely servicing of financial obligations. Additionally, the company's recently listed secured non-convertible debentures (NCDs) on the BSE Debt segment carry the same IND A+ / Stable rating, underscoring consistent creditworthiness across its debt instruments. This rating indicates a low credit risk profile, supported by the company's diversified operations and established presence in the pharmaceutical contract manufacturing sector.
Get answers to the most frequently asked questions by retail investors
The minimum investment amount is ₹1,02,530
Interest is paid on a half-yearly basis.
The bonds will mature on July 15, 2026.
There is no lock-in period; however, investors should consider the maturity date when planning their investment.
Investors can explore investment options through financial platforms such as Aspero.
Explore Dishman Carbogen Amics Senior Secured Bonds on Aspero today.
Explore now
